Paul Bloem (WHO/IVB) presented evidence on HPV vaccine efficacy, safety, and updated WHO recommendations. He underscored >90% protection against HPV 16/18 and herd effects at high coverage. Long-term studies show stable antibody levels over 10+ years for 1, 2, and 3 doses, with single-dose trials demonstrating ~97% efficacy against persistent infection. These findings informed WHO’s […]
Topic: Single Dose Guidelines
WHO position paper on new recommendation and Global overview on HPV vaccine efficacy and safety – Q&A Session
The Q&A session addressed community concerns on HPV vaccine safety, duration of protection, and gender equity in vaccination. Questions covered reported adverse events (e.g., seizures, headaches, menstrual symptoms), long-term antibody persistence, and the relevance of early cancer incidence in efficacy studies. Paul Bloem clarified that extensive global safety reviews show no causal links between HPV […]
One dose: WHO current guidelines, available vaccines and opportunities for MAC catchup programs with one dose
Cette présentation résume les nouvelles recommandations de l’OMS sur la vaccination contre le HPV, basées sur les conclusions du Groupe stratégique consultatif d’experts (SAGE) en avril 2022. Le principal changement est l’adoption du schéma à une seule dose comme alternative efficace au schéma traditionnel à deux doses, pour les filles âgées de 9 à 14 […]
One dose: WHO current guidelines, available vaccines and opportunities for MAC catchup programs with one dose
In this presentation, WHO’s updated recommendations on HPV vaccination are outlined, reflecting the latest evidence reviewed by the Strategic Advisory Group of Experts (SAGE) in April 2022. The key change is the endorsement of a single-dose schedule as an equally effective alternative to the traditional two-dose regimen for girls aged 9–14 and for young women […]